Register
Login:
Share:
Email Facebook Twitter




Sareum Share Chat (SAR)



Share Price: 0.265Bid: 0.26Ask: 0.27Change: 0.00 (0.00%)No Movement on Sareum
Spread: 0.01Spread as %: 3.85%Open: 0.275High: 0.275Low: 0.26Yesterday’s Close: 0.265


Share Discussion for Sareum


Thread View

Please login or register to post a message on Share Chat.

Posts per page:

Obelix
Posts: 9,006
Off Topic
Opinion:No Opinion
Price:0.265
gige
Today 17:01
Recommended Corinthiano
 
gige
Posts: 4,670
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.265
SAR
Today 15:09
Some peoples here do more damage than good ,they ramp then sell ,then ask for lower price ,
LuluIsland
Posts: 814
Off Topic
Opinion:No Opinion
Price:0.265
RE: No no no
Today 09:43
I will give you this Thoth....your confusing the hell out of me but you sound confident!
Hopkirk
Posts: 1,358
Off Topic
Opinion:No Opinion
Price:0.265
RE: No no no
Today 02:33
thanks :)
Thoth2
Posts: 80
Off Topic
Opinion:No Opinion
Price:0.265
RE: No no no
Today 02:02
Most likeely outcome is you lose all your money.
Hopkirk
Posts: 1,358
Off Topic
Opinion:No Opinion
Price:0.265
RE: No no no
Today 01:01
Hi Thoth. What chance of success would you give CHK1 for passing each of the phases and what do you see the timescale to market as being?
Thoth2
Posts: 80
Off Topic
Opinion:No Opinion
Price:0.265
RE: No no no
Today 00:14
Num4 i think you are confusing the posts.

For jak1 failure search incyte in news on google. The point is part of azn strategy on solid tumours has unravelled. So they have a gap to fill. Our tyk2 compound is different but similar family.

My link on chk1 failure with azn is different. It shows it is an important target for azn. But their compound had too serious side effects.

This is my point. Its not first to market but best in class. Second mover advantage. If our delays getting here are tweaking molecules to minimise side effects. And we are right. And we are partnered with the experts. We are billionaires

The amounts azn et al have spent on research and trials. The data they have to compare our compounds against ( you can buy our chk1 and tyk2 compounds on the web to test ).

Existing relationship with cruk gives azn merk and overlapping interests in chk1 aurora+flt3.

If we dont get the side effects we are billionaires. There will be a fundraising at some point. But that may not be a share issue but a strategic investment by a big pharma (which would double sp at a stroke )

Sentinel oncology is a wldcard. I suspect they are involved somehow ( more targeted delivey,
Linked with cruk and azn , cambridge based) but that is pure speculation by me.

Side effects in p1 key. And does big pharma want to invest in some way prior to p1 results as a hedge. Informed gambling
Obelix
Posts: 9,006
Off Topic
Opinion:No Opinion
Price:0.265
Funny day
Fri 20:46
More Buys than Sells and We close down 3.64%.... lol
mangio61
Posts: 1,296
Off Topic
Opinion:No Opinion
Price:0.265
RE: No no no
Fri 18:26
can you post relative links on this failure please. Thanks
Num4
Posts: 626
Off Topic
Opinion:No Opinion
Price:0.265
No no no
Fri 17:39
It's bad news that Jak1 has failed for them and for us. We wanted there compound to succeed so it validates the target. It's Tyk2 also not Chk1.




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.